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Quantitative Methods, University of Milano-Bicocca, Via Bicocca degli Arcimboldi 8, Milan 20126, Italy; 4Department of
Internal Medicine and Huntsman Cancer Institute, University of Utah School of Medicine, 2000 Circle of Hope, Salt Lake City,
UT 84108, USA; 5Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Room 3-55 1425 Madison Avenue, New York,
NY 10029, USA; 6Department of Epidemiology, UCLA Fielding School of Public Health, 71-225 CHS, Box 951772, Los Angeles, CA
90095, USA and 7Department of Clinical Sciences and Community Health, University of Milan, Via Vanzetti, 5, Milan 20133, Italy
Background: The association between coffee intake, tea intake and cancer has been extensively studied, but associations are not
established for many cancers. Previous studies are not consistent on whether caffeine may be the source of possible associations
between coffee and cancer risk.
Methods: In the Prostate, Lung, Colorectal, and Ovarian cancer screening trial, of the 97 334 eligible individuals, 10 399 developed
cancer. Cancers included were 145 head and neck, 99 oesophageal, 136 stomach, 1137 lung, 1703 breast, 257 endometrial, 162
ovarian, 3037 prostate, 318 kidney, 398 bladder, 103 gliomas, and 106 thyroid.
Results: Mean coffee intake was higher in lower education groups, among current smokers, among heavier and longer duration
smokers, and among heavier alcohol drinkers. Coffee intake was not associated with the risk of all cancers combined (RR¼ 1.00,
95% confidence interval (CI)¼ 0.96–1.05), whereas tea drinking was associated with a decreased risk of cancer overall (RR¼ 0.95,
95% CI¼ 0.94–0.96 for 1þ cups per day vs o1 cup per day). For endometrial cancer, a decreased risk was observed for coffee
intake (RR¼ 0.69, 95% CI¼ 0,52–0.91 forX2 cups per day). Caffeine intake was not associated with cancer risk in a dose–response
manner.
Conclusions: We observed a decreased risk of endometrial cancer for coffee intake, and a decreased risk of cancer overall with
tea intake.
The association between coffee intake and various cancers has
been extensively studied, but associations are not established for
many cancers. Coffee intake may not be associated with the
risk of overall cancer (RR¼ 1.03, 95% confidence interval
(CI)¼ 0.97–1.10), according to a meta-analysis of prospective
studies (Malerba et al, 2013b). However, recent studies have been
suggestive of a protective effect of coffee against head and neck
cancer, oesophageal squamous cell carcinoma, and endometrial
cancer, with dose–response relations (La Vecchia and Tavani,
2007; Bravi et al, 2009a, b; Galeone et al, 2010; Turati et al,
2011). There have been multiple recent meta-analyses showing a
reduced risk of prostate cancer risk with greater coffee intake (Cao
et al, 2014; Discacciati et al, 2014; Huang et al, 2014; Lu et al, 2014;
Zhong et al, 2014). The protective effects observed tended to be for
very high coffee intake (more than 4–7 cups of coffee per day). On
the other hand, some cancers are thought to have no association
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with coffee intake (oesophageal adenocarcinoma, stomach, lung,
ovarian, and thyroid cancer and glioma).
Tea intake may also be protective against some cancers,
although again data are inconsistent. Green tea may be protective
against breast cancer and black tea may increase risk according to a
meta-analysis of five cohort studies and eight case–control studies
(Sun et al, 2006). A meta-analysis of tea intake including seven
case–control and five cohort studies was suggestive of a protective
effect (RR¼ 0.85, 95% CI¼ 0.71–1.01) against ovarian cancer
(Steevens et al, 2007), although a more recent meta-analysis
suggested no association with ovarian cancer (Braem et al, 2012).
Similarly, a decreased kidney cancer risk due to tea intake was also
suggested in a pooled analysis of 13 prospective studies (RR¼ 0.85,
95% CI¼ 0.71, 1.02; Lee et al, 2007). No consistent associations
were observed between tea intake and head and neck cancer
(Galeone et al, 2010), bladder cancer (Wu et al, 2013; Bai et al,
2014), or thyroid cancer (Mack et al, 2003).
Some studies have reported an association with cancer for
caffeinated coffee but not for decaffeinated coffee. Few studies were
able to examine total caffeine intake from all dietary sources.
A large proportion of studies that have assessed the association
between total caffeine intake and cancer have been null (Najem
et al, 1982; Folsom et al, 1993; Slattery and West, 1993; Michels
et al, 2002; Hirose et al, 2007; Ishitani et al, 2008; Song et al, 2008;
Boggs et al, 2010). Studies reporting an association between
caffeine intake and cancer include an inverse association with
ovarian cancer (Jordan et al, 2004; Tworoger et al, 2008), as well as
an increased risk for ovarian cancer (Kuper et al, 2000). As caffeine
is a component of coffee that can induce biological effects and may
induce apoptosis (Bohn et al, 2014), it is of interest to assess
whether caffeine is associated with cancer risk.
Considering that coffee and tea consumption are a highly
prevalent lifestyle factor in the world, it is of interest to clarify the
role of coffee and tea in cancer overall and in specific cancer sites.
We investigated the relation between coffee and tea consumption
and cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial (PLCO) prospective study.
MATERIALS AND METHODS
The PLCO trial is a large-scale clinical trial aimed at determining
whether select cancer screening tests reduce deaths from prostate,
lung, colorectal, and ovarian cancer. The trial started in 1992 and
ended enrollment in 2001. Approximately 155 000 women and
men between the ages of 55 and 74 were recruited into the PLCO
trial at 10 centres across the United States (Alabama, Michigan,
Colorado, Hawaii, Wisconsin, Minnesota, Pennsylvania, Utah,
Missouri, and Washington DC). At entry, participants were
randomised to one of two study groups. One group received
routine health care from their health providers. The other received
a series of exams to screen for prostate, lung, colorectal, and
ovarian cancers. Screening of participants ended in late 2006.
Follow-up will continue for up to 10 more years to determine the
benefits or harms of screening. Written informed consent was
obtained from all study participants. Ethical approval for human
subjects’ research was obtained at each of the centres.
The data used for this study include the follow-up information
up to May 2011. Subjects randomised to either study arm
(intervention or control) were eligible if they had completed the
baseline questionnaire and the diet history questionnaire, which
was administered to participants in both groups starting in 1998.
The dietary history questionnaire has been validated in three
different studies (Subar et al, 2001; Thompson et al, 2002;
Millen et al, 2009). Of the 154 900 study participants recruited
into the PLCO study, 111 513 participants completed both the
baseline questionnaire and the diet history questionnaire. Of the
111 513 participants with valid questionnaires, participants were
excluded because: (a) they had cancer before entry into the PLCO
study (n¼ 9673) or (b) they did not have follow-up time
(n¼ 4506). Thus, the remaining cohort consisted of 97 334
individuals, of which 10 399 developed any malignant cancer. We
excluded from the present analysis cancers of the pancreas, liver,
and colorectum, which will be or have been the object of in depth
analysis by other investigators (Dominianni et al, 2013). We
focused on cancers where recent published studies suggested
associations with coffee. There were cases of: 145 head and neck
cancers, 99 esophageal cancers, 136 stomach cancers, 1137
lung cancers, 1703 breast cancers, 257 endometrial cancers, 162
ovarian cancers, 3037 prostate cancers, 318 kidney cancers, 398
bladder cancers, 103 gliomas, and 106 thyroid cancers. The total
number of patients with the cancers of interest was 7601. Cancer
cases were diagnosed from enrollment completion in 2001 to
May 2011. An annual study update was used to ascertain cancer
diagnoses, and was mailed annually to the study participants.
Participants were asked if they were diagnosed with cancer, the
type of cancer, date of diagnosis, hospital or clinic of diagnosis, and
physician contact information. For every cancer reported, medical
record abstraction included the cancer diagnosis date and ICD-O-2
code. Death status was obtained by the administration of the
Annual Study Update questionnaire, reports from relatives, friends,
or physicians, and National Death Index plus searches. Study
centres attempted to obtain a death certificate for each death that
occurred on or before 31 December 2009.
If the study participant was diagnosed with cancer after study
entry, which ranged from 1992 to 2001, and before completion of
the dietary questionnaire, they were not eligible. The entry date is
taken as the maximum of randomisation date, baseline questionnaire
completion date, and dietary history questionnaire completion date.
In this analysis, dietary history questionnaire completion is necessary
for the coffee and tea information, thus the entry date becomes the
dietary history questionnaire completion date.
Although the screening arm was screened for prostate, lung,
colorectal, and ovarian cancers, they did not necessarily have
higher incidence rates of cancer. Of the 10 399 cancer cases, 5243
were in the control arm and 5156 were in the intervention arm. For
the specific cancers, the numbers for control vs intervention arm
were: 68 vs 77 in head and neck cancers, 53 vs 46 in esophageal
cancers, 61 vs 75 in stomach cancers, 560 vs 577 in lung cancers,
870 vs 833 in breast cancers, 143 vs 111 in endometrial cancers, 77
vs 85 in ovarian cancers, 1521 vs 1485 in prostate cancers, 140 vs
178 in kidney cancers, 213 vs 184 in bladder cancers, 56 vs 47 in
gliomas, and 59 vs 47 in thyroid cancers. According to a w2 test, the
number of cancer cases by study arm was not statistically
significantly different, except for breast cancer (1.85% of control
group were diagnosed with breast cancer, 1.70% of intervention
group were diagnosed with breast cancer; P-value for w2¼ 0.0411),
and endometrial cancer (0.3% of control group and 0.23% of
intervention group were diagnosed; P-value for w2¼ 0.0182).
The baseline questionnaire included information on age, sex,
race, education, marital status, cigarette smoking (frequency,
years), family history of cancer, weight (at age 20 years, age 50
years and current), and height. The diet history questionnaire
administered beginning in 1998, included information on numer-
ous food items including coffee, tea, and caffeine intake. The
questions on coffee were ‘Over the past 12 months, how many cups
of coffee, caffeinated, or decaffeinated did you drink?’, ‘How often
was the coffee you drank decaffeinated?’. The size of the cup was
not indicated. The answer options for the cups of coffee were none,
o1 cup per month, 1–3 cups per month, 1 cup per week, 2–4 cups
per week, 5–6 cups per week, 1 cup per day, 2–3 cups per day, 4–5
cups per day, and 6 or more cups per day. The questions on tea
were ‘How many glasses of ICED tea, caffeinated, or decaffeinated
did you drink?’, ‘How often was the iced tea you drank
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decaffeinated or herbal tea?’, ‘How many cups of HOT tea,
caffeinated, or decaffeinated did you drink?’, ‘How often was the
hot tea you drank decaffeinated or herbal tea?’. The questions on
iced and hot tea were summed to obtain the total tea intake. The
answer options for the cups of tea were the same as for coffee, as
specified above. There were also questions on whether sugar,
honey, artificial sweeteners, non-dairy creamer, cream or half and
half, and/or milk were added to the coffee or tea.
Nutrient databases were developed for the dietary questionnaire
based on the NDS-R sample data by the PLCO research team. The
nutrient values (including caffeine) were calculated from the
database for each subject based on the frequency with which they
said they ate/drank each food or beverage and also the portion size.
For example, if a subject said they drank a coffee three times per
week then the nutrient values for a coffee were multiplied by the
frequency of three times per week and then converted to a daily
Table 1. Characteristics of the PLCO cohort and cancer cases
Cohort Any cancer
n %
Mean coffee
intake
(cups per day)
mean Tea
intake
(cups per day) n %
Mean coffee
intake
(cups per day)
Mean tea
intake
(cups per day)
Total 97 334 1.9 0.65 10399 2.0 0.63
Age at enrollment (years)
55–59 17 711 18.2 1.9 0.71 1440 13.8 2.1 0.69
60–64 27 870 28.6 1.9 0.66 2800 26.9 2.1 0.62
65–69 26 261 27.0 1.9 0.64 3031 29.1 2.0 0.62
4¼70 25 492 26.2 1.8 0.62 3128 30.1 1.9 0.61
Sex
Male 46 771 48.1 2.1 0.56 6209 59.7 2.2 0.55
Female 50 563 51.9 1.7 0.74 4190 40.3 1.8 0.74
Race
White, non-Hispanic 88 515 90.9 2.0 0.65 9554 91.9 2.1 0.63
Other 8819 9.1 1.2 0.65 845 8.1 1.3 0.65
Education
p11 years 5773 5.9 2.1 0.55 671 6.5 2.2 0.51
12 years or completed high school 22 656 23.3 2.0 0.61 2316 22.3 2.1 0.58
Post high school training 33 501 34.4 1.9 0.66 3557 34.2 2.0 0.63
College graduate or postgraduate 35 216 36.2 1.8 0.69 3855 37.1 1.9 0.68
Missing 188 0.2
Tobacco smoking status
Never smoker 46 751 48.0 1.5 0.68 4367 42.0 1.5 0.65
Current smoker 8820 9.1 3.0 0.61 1357 13.0 3.1 0.60
Former smoker 41 743 42.9 2.1 0.63 4675 45.0 2.2 0.62
missing 20 0.0
Tobacco smoking frequency (cigarettes per day)
Never smoker 46 751 48.0 1.5 0.68 4367 42.0 1.5 0.65
1–10 13 062 13.4 1.9 0.67 1254 12.1 1.9 0.62
11–20 18 702 19.2 2.3 0.61 2228 21.4 2.3 0.61
21–30 10 088 10.4 2.5 0.60 1334 12.8 2.6 0.62
430 8615 8.9 2.6 0.63 1216 11.7 2.7 0.62
Missing 116 0.1
Tobacco smoking duration (years)
Never smoker 46 751 48.0 1.5 0.68 4367 42.0 1.5 0.65
1–10 7604 7.8 1.9 0.69 731 7.0 1.9 0.65
11–20 10 585 10.9 2.1 0.64 1166 11.2 2.1 0.60
420 31 318 32.2 2.5 0.61 4135 39.8 2.6 0.61
Missing 1076 1.1
Tobacco smoking, years since quitting for former smokers
40 to 2 2473 2.5 2.5 0.67 331 3.2 2.8 0.63
3–5 2520 2.6 2.3 0.60 345 3.3 2.3 0.55
6–10 5036 5.2 2.3 0.65 598 5.8 2.2 0.57
11–20 10 547 10.8 2.2 0.60 1182 11.4 2.3 0.61
420 20 351 20.9 2.1 0.65 2219 21.3 2.0 0.63
Missing 836 0.9
Alcohol drinking
Never drinker 4081 4.2 1.2 0.60 380 3.7 1.4 0.55
o0.5 Drink per day 60 482 62.1 1.7 0.70 6214 59.8 1.9 0.70
0.5–0.9 Drink per day 9583 9.8 2.1 0.63 1029 9.9 2.2 0.59
1–1.49 Drinks per day 5500 5.7 2.3 0.60 619 6.0 2.4 0.51
1.5–1.9 Drinks per day 3823 3.9 2.3 0.58 414 4.0 2.3 0.53
2–2.4 Drinks per day 4480 4.6 2.3 0.57 501 4.8 2.3 0.60
X2 Drinks per day 9385 9.6 2.4 0.48 1242 11.9 2.4 0.44
Abbreviation: PLCO¼Prostate, Lung, Colorectal, and Ovarian.
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value. The nutrient totals were then summed over all foods to give
the total daily nutrient intake for each subject. The largest
contributors to caffeine intake were coffee, tea, and soda/soft
drinks.
Statistical methods. We estimated hazard ratios and the corre-
sponding 95% CIs with the Cox proportional hazards model.
Follow-up time was calculated from the age at dietary ques-
tionnaire until the occurrence of one of the following events:
diagnosis of cancer, death, or the end of follow-up. We adjusted on
age (continuous), sex, race (white non-Hispanic vs others),
education (categories as shown in Table 1), cigarette pack-years
(continuous), and alcohol drinking frequency (mg of alcohol per
day, continuous), where appropriate. All analyses were conducted
with the SAS program version 9.4 (SAS Institute Inc., Cary, NC,
USA).
RESULTS
There were 97 334 individuals in the cohort, of which 10 399 were
diagnosed with cancer. By age group, there did not appear to be
any major differences in mean coffee consumption (Table 1). By
sex, men drank more coffee per day than women, whereas women
drank more tea than men. By race/ethnicity groups, White non-
Hispanic individuals had a higher frequency of coffee drinking.
Mean coffee intake was also higher in lower education groups,
among current smokers, among heavier frequency smokers, among
longer duration smokers, and among heavier drinkers. In contrast,
mean tea consumption was higher in higher education groups, and
never smokers. As expected, there were a higher proportion of
heavier drinkers and heavier smokers in the cancer case group
compared with the overall cohort.
Coffee intake was not associated with the risk of all cancers
combined (Table 2). The number of cancer cases who drank coffee
in the o1 cup per day groups were 1583 for all cancers, 17 for
head and neck cancer, 16 for esophageal cancer, 9 for stomach
cancer, 125 for lung cancer, 298 for breast cancer, 60 for
endometrial cancer, 24 for ovarian cancer, 445 for prostate
cancer, 46 for kidney cancer, 50 for bladder cancer, 17 for
glioma, and 15 for thyroid cancer. For esophageal cancer, there
appeared to be an increased risk for drinking 1–1.9 cups per day
compared with o1 cup per day, although there was no overall
dose–response trend. For lung cancer, an increased risk was
observed for every one cup increase in coffee intake, but without
a significant P-value for trend. A reduced risk of kidney cancer
was suggested by the RR for every 1 cup per day increase in
coffee intake, but again without a dose–response suggested for
the categories of coffee drinking. For endometrial cancer, a
decreased risk was observed, with a significant P-value for trend
(P¼ 0.009), although the point estimates did not suggest a trend
and instead suggested similar protective risk ratios for the two
coffee drinking categories.
We conducted the analysis separately for regular coffee and
decaffeinated coffee, but did not observe any strong associations or
trends. We also estimated risk ratios for higher frequencies of
coffee intake (4 or more cups/day) but did not observe any
associations, except for kidney cancer (RR¼ 0.43, 95% CI¼ 0.20–
0.93) where an overall dose–response was not observed (P for
trend¼ 0.1015). For all cancers, the RRs were 0.99 (0.93–1.06) for
drinking 2–3.9 cups per day and 1.00 (0.91–1.11) for drinking 4 or
more cups per day.
Among the 46 751 never smokers in the cohort, 4367 developed
cancer. Among these never smokers, associations of coffee intake
with the risk of cancer overall or for any specific cancer were not
detected. The overall cancer RRs for coffee drinking among never
smokers were 1.03 (95% CI¼ 0.95–1.13) for 1–1.9 cups per day
and 1.01 (95% CI¼ 0.95–1.08) for X2 cups per day (P for
trend¼ 0.6918). The endometrial cancer RRs for coffee drinking
among never smokers were 0.67 (95% CI¼ 0.41–1.09) for 1–1.9
cups per day and 0.71 (95% CI¼ 0.50–1.01) for X2 cups per day
(P for trend¼ 0.0538).
For endometrial cancer, we further adjusted on BMI
(o18.5 kgm 2, 18.5–24.9 kgm 2, 25–29.9 kgm 2, 30þ kgm 2),
Table 2. Coffee intake and cancer risk in the PLCO cohort
Coffee intake (caffeinated and decaffeinated)
o1 Cup per day 1–1.9 Cups per day Z2 Cups per day
Total
cases/cohort Per cup Cases/cohort Cases/cohort RR 95% CI Cases/cohort RR 95% CI
P for
trend
All cancersa 10 399/96 024 1.00 (0.99–1.01) 3120/31 223 1580/14 749 1.01 0.95–1.08 5699/50 052 1.00 0.96–1.05 0.9932
Head and necka 145/96 024 0.99 (0.91–1.09) 31/31 223 18/14 749 1.08 0.60–1.94 96/50 052 1.04 0.68–1.58 0.9047
Oesophageala 99/96 024 1.03 (0.92–1.15) 22/31 223 23/14 749 1.9 1.06–3.43 54/50 052 0.93 0.56–1.56 0.4746
Stomachb 136/96 024 1.04 (0.95–1.15) 36/31 223 28/14 749 1.53 0.93–2.51 72/50 052 1.07 0.70–1.62 0.9095
Lungb 1137/96 024 1.04 (1.01–1.07) 222/31 223 137/14 749 1.03 0.83–1.27 778/50 052 1.10 0.94–1.28 0.1960
Breastc 1703/50 563 0.98 (0.95–1.01) 599/17 663 276/8547 0.95 0.82–1.10 828/24 353 0.97 0.87–1.08 0.6380
Endometriala 254/32 392 0.92 (0.85–1.00) 106/10 682 36/5372 0.66 0.45–0.96 112/16 239 0.69 0.52–0.91 0.0089
Ovarian 162/50 563 1.04 (0.95–1.14) 50/17 663 30/8547 1.21 0.77–1.91 82/24 353 1.17 0.82–1.67 0.3982
Prostate 3037/46 667 0.99 (0.97–1.01) 889/13 854 417/6378 1.02 0.91–1.15 1731/26 435 1.02 0.94–1.10 0.7020
Kidneyb 318/96 024 0.94 (0.88–1.00) 104/31 223 50/14 749 0.99 0.70–1.38 164/50 052 0.84 0.65–1.09 0.1746
Bladderb 398/96 024 0.99 (0.94–1.05) 92/31 223 62/14 749 1.22 0.88–1.69 244/50 052 1.08 0.85–1.39 0.6390
Glioma 103/97 334 0.89 (0.78–1.01) 38/31 547 16/14 945 0.86 0.48–1.55 49/50 842 0.76 0.50–1.17 0.2092
Thyroid 106/97 334 1.00 (0.89–1.12) 36/31 547 17/14 945 1.04 0.58–1.85 53/50 842 1.00 0.65–1.53 0.9801
Abbreviations: CI¼ confidence interval; PLCO¼Prostate, Lung, Colorectal, and Ovarian; RR¼ relative risk. All RRs are adjusted for age (continuous), sex, race, and education.
aAdditionally adjusted for smoking status (never/former/current), smoking frequency (cigarettes per day categories), smoking duration (years of smoking categories), time since stopping
smoking for past smokers (years categories), and drinking frequency (drinks per day categories).
bAdditionally adjusted for smoking status (never/former/current), smoking frequency (cigarettes per day categories), smoking duration (years of smoking categories), time since stopping
smoking for past smokers (years categories).
cAdditionally adjusted for drinking frequency (drinks per day categories).
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years on birth control (o1, 2–3, 4–5, 6–9, 10þ years), number of
live births, years taking female hormones (o1, 2–3, 4–5, 6–9, 10þ
years), age at menopause (o40, 40–44, 45–49, 50–54, 55þ years).
The RRs additionally adjusted on these BMI and reproductive
factors were 0.67 (95% CI¼ 0.45–0.99) for drinking 1–1.9 coffee
cups per day and 0.72 (95% CI¼ 0.55–0.95) for drinkingX2 coffee
cups per day (P for trend¼ 0.0205).
When stratified by sex, we did not observe an association
between coffee intake and the risk of cancer overall or for specific
cancers. The only exception was that we observed an association
between coffee intake and the risk of glioma among men. The RRs
for glioma among men were 0.89 (95% CI¼ 0.44–1.91) for 1–1.9
cups of coffee per day and 0.53 (0.31–0.92) for drinkingX2 coffee
cups per day (P for trend¼ 0.0219).
Tea intake, including both caffeinated and decaffeinated, was
associated with a decreased risk of cancer overall (RR¼ 0.95, 95%
CI¼ 0.94–0.96; Table 3). The risk of specific cancer sites,
however, was not associated with tea intake. The number of
cancer cases who drank coffee in theo1 cup per day groups were
3040 for all cancers, 33 for head and neck cancer, 24 for
esophageal cancer, 38 for stomach cancer, 255 for lung cancer,
684 for breast cancer, 97 for endometrial cancer, 68 for ovarian
cancer, 784 for prostate cancer, 88 for kidney cancer, 88 for
bladder cancer, 30 for glioma, and 24 for thyroid cancer. Every
one cup increase in tea consumption per day appeared to increase
the risk of endometrial cancer, but comparing individuals who
drank less than one cup per day vs one cup or more did not show
any association. When stratified by sex, tea intake was not
associated with any specific cancers for men or for women.
The overall cancer risk for drinking 1 or more cups of tea per
day was 1.03 (95% CI¼ 0.96–1.10) for women and 1.00
(95% CI¼ 0.94–1.07) for men.
When we assessed overall caffeine intake, decreased risks were
observed in specific quartiles for stomach cancer, prostate cancer,
and thyroid cancer; although with no dose–response (Table 4).
Increased risks because of caffeine intake were also suggested for
some specific quartiles for ovarian cancer and for kidney cancer,
although again with no consistent dose–response.
DISCUSSION
We observed a decreased risk of endometrial cancer for women
drinking 1 or more cups per day of coffee compared with those
who drank less than a cup per day. Although we observed some
increased and decreased risks in specific quartiles of caffeine intake,
there were no dose–response trends observed, suggesting that
caffeine is not the key constituent in associations between cancer
and coffee or tea. Tea intake was protective against cancer overall
with a 5% decrease for 1 or more cups of tea per day compared
with less than 1 cup per day. However, cancer site-specific
decreased risks were not significant.
Our observation of no association between coffee intake and
total cancer risk is consistent with most previous studies (Malerba
et al, 2013b). Although some studies have reported on inverse
associations between coffee intake and head and neck cancer
(Galeone et al, 2010), oesophageal squamous cell carcinoma and
prostate cancer, we did not observe strong associations with coffee
for these cancers. Our results also corroborate with no association
of coffee intake with oesophageal adenocarcinoma (Turati et al,
2011), stomach (Botelho et al, 2006), ovarian (Steevens et al, 2007),
kidney (Huang et al, 2014), thyroid cancer (Mack et al, 2003), and
glioma (Malerba et al, 2013a), as reported in previous studies and
meta-analyses. Although tea appeared to be protective against
overall cancer in our study, cancer-specific reductions in risk were
not observed.
The inverse relationship between coffee drinking and endome-
trial cancer may be related to various components of coffee.
Besides caffeine, coffee contains more than a thousand chemicals
(IARC, 1991), some of which have antioxidant and antimutagenic
activities in animal models and cell culture systems (Cavin et al,
2002). These include several phenolic compounds (such as
chlorogenic, caffeic, ferulic, and cumaric acids), melanoidins, and
diterpenes (such as cafestol and kahweol; Daglia et al, 2000;
Anese and Nicoli, 2003) whose concentration in the beverage
varies depending on type of raw coffee (Arabica or Robusta),
roasting, and preparation, as unfiltered coffee contains less
Table 3. Tea (caffeinated and decaffeinated) intake and cancer risk in the PLCO cohort
o1 Cup per day Z1 Cup per day
Total cases/cohort Per cup Cases/cohort Cases/cohort RR 95% CI
All cancersa 10 399/96 024 1.00 (0.98–1.02) 8232/75 280 2167/20 744 0.95 0.94–0.96
Head and necka 145/96 024 1.01 (0.88–1.17) 118/75 280 27/20 744 1.07 0.70–1.63
Oesophageala 99/96 024 1.01 (0.84–1.20) 83/75 280 16/20 744 0.88 0.51–1.50
Stomacha 136/96 024 0.99 (0.85–1.16) 105/75 180 31/20 744 1.22 0.81–1.82
Lungb 1137/96 024 0.99 (0.95–1.04) 925/75 280 212/20 744 0.96 0.83–1.12
Breastc 1698/50 563 1.01 (0.97–1.05) 1252/37 917 446/12 646 1.06 0.95–1.18
Endometriala 254/32 293 1.09 (1.00–1.19) 180/24 272 74/8012 1.24 0.95–1.63
Ovarian 162/50 563 0.91 (0.79–1.06) 125/37 917 37/12 646 0.87 0.60–1.26
Prostate 3037/46 667 0.98 (0.95–1.01) 2524/38 315 513/8352 0.92 0.84–1.02
Kidneyb 318/96 024 0.98 (0.89–1.09) 246/75 280 72/20 744 1.16 0.89–1.52
Bladderb 398/96 024 0.97 (0.88–1.07) 326/75 280 72/20 744 0.98 0.76–1.26
Glioma 103/97 334 1.04 (0.88–1.22) 81/76 318 22/21 016 1.04 0.65–1.66
Thyroid 106/97 334 1.06 (0.91–1.22) 77/76 318 29/21 016 1.23 0.80–1.89
Abbreviations: CI¼ confidence interval; PLCO¼Prostate, Lung, Colorectal, and Ovarian; RR¼ relative risk. All RRs are adjusted for age (continuous), sex, race, education.
aAdditionally adjusted for smoking status (never/former/current), smoking frequency (cigarettes per day categories), smoking duration (years of smoking categories), time since stopping
smoking for past smokers (years categories), and drinking frequency (drinks per day categories).
bAdditionally adjusted for smoking status (never/former/current), smoking frequency (cigarettes per day categories), smoking duration (years of smoking categories), time since stopping
smoking for past smokers (years categories).
cAdditionally adjusted for drinking frequency (drinks per day categories).
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amounts of lipid component, such as diterpenes (Viani, 1993).
In particular, cafestol and kahweol may reduce the genotoxicity of
some carcinogens (Cavin et al, 2002) and may activate enzymes
involved in cancerogenic detoxification (Cavin et al, 1998; Majer
et al, 2005), such as glutathione S-transferase and N-acetyltrans-
ferase (Huber and Parzefall, 2005). Still, no definite biological
mechanism of the potential healthy role of coffee on endometrial
cancers is available (La Vecchia and Tavani, 2007). Our results
suggest that caffeine is not the component of coffee that confers a
protective effect against endometrial cancer. Tea is also composed
of a complex mixture including polyphenols and flavinoids,
which are antioxidants (Gardner et al, 2007). Flavinoids may also
have anti-inflammatory properties and may inhibit tumorigenesis
(Gardner et al, 2007).
Strengths of our study are the prospective design, detailed
tobacco smoking adjustments, and large sample size. As the
questionnaire data were collected before cancer diagnosis, we can
exclude the possibility of recall bias. We investigated cancer overall
as well as specific cancer sites. We explored whether caffeine was
associated with cancer risk. We reported on differences in the mean
coffee intake in cups per day by age, sex, race/ethnicity, education,
tobacco, and alcohol habits. As tobacco smokers had higher
frequencies of coffee intake, detailed adjustment for tobacco smoking
as a potential confounder was very important. The sample size of the
cohort as well as the number of cancer patients was very large.
Some limitations of our study are that we did not have
information on duration of coffee or tea drinking, cumulative
coffee intake over the lifetime, and more details on the types of
coffee (espresso, drip and so on). As the frequency of coffee and tea
was captured at baseline for the last 12 months, it is possible that
individuals later became coffee or tea drinkers, and we might
misclassify them as non-drinkers. Conversely, individuals who
were drinking coffee and/or tea at baseline may have stopped
shortly before the questionnaire, in which case the coffee or tea
drinking reported may not have been reflective of their usual habits
over a long period of time. Although we had fairly large numbers
of cancer cases, for specific subsites such as oesophageal, head and
neck, and prostate cancer, we were not able to refine the groups
further by histology, finer subsites or by tumour grade. In addition,
multiple testing may also account for some of the associations
observed, in the absence of any overall consistent trend in risk for
coffee drinking. Also, we adjusted for education as a potential
confounder as an indicator of socioeconomic status, but we cannot
rule out the possibility that there is still confounding because of
socioeconomic status or related health behaviours.
In summary, we observed a decreased risk of endometrial cancer
for coffee intake and a decreased risk of cancer overall associated
with tea intake. Future studies capturing the age at starting coffee
and tea intake, and time periods of changes in habit (increase or
decrease) would be useful.
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